Nasus Pharma To Present Positive Clinical Results From Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting

TEL AVIV, Israel, Feb. 27, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based intranasal ("PBI") products addressing acute, community based, medical conditions, today announced that it will be presenting the results of two of its clinical studies at the 2025 American Academy of Allergy, Asthma and Immunology ("AAAAI") Annual Scientific Meeting, taking place from February 28 to March 3, 2025, in San Diego, California.

Nasus Pharma will be presenting integrated data, including pharmacokinetics and pharmacodynamics, of intranasal epinephrine in healthy volunteers and under allergenic conditions in atopic patients.  

"We are excited to share the integrated efficacy and safety data from our initial studies during the AAAAI's upcoming meeting. We look forward to collaborating with the medical community as we continue to develop our Epinephrine program, which we believe offers important advantages over existing therapies, to address what we believe is an important medical need for millions of people who suffer from severe allergies," said Dan Teleman, Nasus Pharma's Chief Executive Officer

Information about Nasus Pharma's poster presentation can be found below. Attendees are encouraged to visit our poster presentation to learn more about FMXIN002. Abstracts can be viewed at annualmeeting.aaaai.org.

Poster Presentation – March 1, 2025

Time: 9:45 a.m. - 10:45 a.m. PST

Title: Fast Acting, 5 years stable Intra-Nasal Powder Spray Epinephrine for Anaphylaxis: Integrated Analysis of Two Clinical Trials

Authors: Tair Lapidot, PhD, Yuval Tal, MD, PhD, Dalia Megiddo, MD, Galia Temtsin Krayz, PhD, Yoseph Caraco, MD

Poster ID: 293

About FMXIN002
FMXIN002, also known as NS002, is a powder formulation of epinephrine nasal spray developed by Nasus Pharma based on its unique intranasal powder proprietary technology. The company believes that the FMXIN002 may enable people to deliver epinephrine in emergency situations easily, rapidly, and with less hesitation, at the onset of an allergic reaction, as compared to currently available epinephrine self-injectors. FMXIN002 uses APTAR Nasal Unidose Powder device – an intuitive and easy-to-use device with 360° functionality and precise one-dose nasal drug delivery.

Anaphylaxis is a severe, life-threatening allergic reaction with a sudden onset that can occur within a few minutes, and unless treated promptly, could be fatal. Some 5 million people in the United States are at risk of having an anaphylaxis reaction. Over 200,000 emergency room visits due to severe reactions from food allergies are reported annually.

About Nasus Pharma
Based on its unique microsphere technology, Nasus Pharma is developing a number of intranasal powder products addressing acute emergency situations in the community such as anaphylactic shock and opioid overdose.

Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety. Nasus portfolio comprises a number of programs in different stages of development.

Contact: 
[email protected]
Nasus Pharma Ltd. Israel
https://www.nasuspharma.com

Logo: https://mma.prnewswire.com/media/1485582/Nasus_Pharma_Logo.jpg

SOURCE Nasus Pharma